KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com) has begun recruitment for its Phase 2 clinical trial of the Company's lead oncology agent PV-10 at a fifth major center, now covering the northeastern United States, in addition to Sydney, Brisbane and Adelaide, Australia, as well as M.D. Anderson in Houston, Texas, USA. Sanjiv Agarwala, M.D. will serve as principal investigator at the new center, located at St. Luke’s Hospital & Health Network, in Bethlehem, PA. Over the next several months, the Company expects to continue expansion of the study to include sites in other major population centers in Australia as well as several sites in the United States.
